VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Published Jul 30, 2026, 4:55 PM

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer.
The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development.
VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program.
Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward…